Aurora Spine Corporation

Established in 2013 and headquartered in Toronto, Canada, Aurora Spine Corporation, through its subsidiary Aurora Spine, Inc., specializes in the development and distribution of advanced, minimally invasive spinal fusion systems and devices within the Canadian market. The company offers a comprehensive portfolio of products designed to address various spinal conditions, particularly degenerative disc diseases. This includes interspinous process lumbar fusion devices such as the ZIP series (ZIP, ZIP ULTRA, ZIP LP, and ZIP-51). Aurora Spine also provides Ti-Coated polyether ether ketone (PEEK) interbody cages, which are crucial for maintaining space and stability between vertebrae while facilitating bone fusion. Its offerings extend to sterile-packed titanium plasma spray coated spinal fusion implants that promote bone growth. Key interbody products comprise EOS, VOX, Echo, Echo SD, and EchoXL for the lumbar region, and Discovery for cervical applications. The company also manufactures SOLO, an anterior lumbar interbody fusion (ALIF) 3D-printed stand-alone device featuring an integrated plate and spacer system for anatomical preservation and spinal support. For sacroiliac joint issues, Aurora Spine provides SiLo, a posterior fusion device. Furthermore, the DEXA-C cervical interbody system, a porous 3D-printed intervertebral body fusion device with customizable lattice density options, is available to match patient bone quality.

Aurora Spine Corporation trades as ASG.V on TSXV. The company is classified in Healthcare / Medical - Devices and reports in CAD.

The current profile places the business in Medical - Devices. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $18.37M of revenue and -$743,918.2 of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Aurora Spine Corporation can be compared against peers such as BriaCell Therapeutics Corp., Rapid Dose Therapeutics Corp., Greenway Greenhouse Cannabis Corporation, Hemostemix Inc., Pangenomic Health Inc., Nova Leap Health Corp..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $17.96M, beta of -0.54, and return on equity of -19.5%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

ASG.V currently shows total debt of $689,122 and beta of -0.54. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.aurora-spine.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.